Mineralys Therapeutics, Inc. Common Stock
$ 30.58
0.07%
17 Apr - close price
- Market Cap 2,519,732,000 USD
- Current Price $ 30.58
- High / Low $ 31.33 / 30.05
- Stock P/E N/A
- Book Value 7.93
- EPS -2.29
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -0.37 %
- 52 Week High 47.65
- 52 Week Low 12.59
About
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. The company is headquartered in Radnor, Pennsylvania.
Analyst Target Price
$49.38
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-18 | 2025-11-11 | 2025-08-12 | 2025-05-12 | 2025-02-12 | 2024-11-11 | 2024-08-13 | 2024-05-09 | 2024-03-21 | 2023-11-07 | 2023-08-07 | 2023-05-15 |
| Reported EPS | -0.4 | -0.52 | -0.66 | -0.79 | -0.98 | -1.13 | -0.83 | -0.7 | -0.61 | -0.57 | -0.31 | -0.51 |
| Estimated EPS | -0.94 | -0.64 | -0.74 | -0.98 | -1.08 | -0.83 | -0.7 | -0.67 | -0.82 | -0.76 | -0.72 | -0.89 |
| Surprise | 0.54 | 0.12 | 0.08 | 0.19 | 0.1 | -0.3 | -0.13 | -0.03 | 0.21 | 0.19 | 0.41 | 0.38 |
| Surprise Percentage | 57.4468% | 18.75% | 10.8108% | 19.3878% | 9.2593% | -36.1446% | -18.5714% | -4.4776% | 25.6098% | 25% | 56.9444% | 42.6966% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.51 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MLYS
2026-04-16 19:39:10
David Rodman has filed a Form 144, indicating a proposed sale of 6,348 shares of Mineralys Therapeutics (NASDAQ: MLYS) common stock, tied to an exercise of employee stock options planned for April 14, 2025. The filing also details multiple completed sales between January 9, 2026, and April 13, 2026, with the largest listed sale being 14,058 shares for $373,086.81 on April 13, 2026. This report provides transparency regarding insider stock transactions.
2026-04-16 03:40:35
Mineralys Therapeutics (NASDAQ:MLYS) CEO Jon Congleton sold 15,730 shares of company stock for a total of $422,035.90 at an average price of $26.83. This transaction, executed under a pre-arranged Rule 10b5-1 plan, reduced his stake by 2.23% to 689,321 shares. The stock traded up 11.3% to $30.42 and holds a "Moderate Buy" consensus rating from analysts with an average price target of $49.14.
2026-04-16 03:40:35
David Malcom Rodman, an insider at Mineralys Therapeutics (NASDAQ:MLYS), sold 14,058 shares of the company's stock on April 13th for approximately $373,099.32. This sale was part of a larger series of dispositions totaling around $1.87 million since January 20th, reducing his position by about 15.6% to 76,140 shares. Mineralys Therapeutics currently has a market capitalization of $2.51 billion, and analysts maintain a consensus "Moderate Buy" rating with an average target price of $49.14.
2026-04-16 03:40:35
Mineralys Therapeutics (NASDAQ:MLYS) insider David Malcom Rodman sold 6,348 shares of company stock for $175,585.68 on April 15th, reducing his direct holdings by 8.34%. This sale was part of a pre-arranged trading plan and is among several recent transactions by Rodman. The stock traded with heavy volume, reported a narrower-than-expected quarterly loss, and holds a "Moderate Buy" consensus rating from analysts.
2026-04-16 02:40:35
Mineralys Therapeutics CEO Jon Congleton sold 15,730 shares of company common stock on April 13, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. The shares were sold at a weighted-average price of $26.8264, totaling approximately $422,000. Following this transaction, Congleton directly holds 689,321 shares of Mineralys stock.
2026-04-16 02:40:35
Mineralys Therapeutics, Inc.'s Chief Medical Officer, Rodman David Malcom, exercised stock options and subsequently sold a total of 20,406 shares of common stock. The transactions, which occurred on April 13 and April 15, 2026, were executed under a Rule 10b5-1 trading plan. Following these sales, Malcom directly holds 69,792 shares of Common Stock in the company.
